Check Claims Before You Publish

 Quick Explanation Copied

 Long Explanation

Lyvia Moudombi's indexed record (OpenAlex: 19 works, 194 citations, h-index 6; Semantic Scholar: 11 papers, 159 citations, h-index 6) describes a mid-stage early-career researcher in tumor immunology and innate immunity Ganglioside senescence immune checkpoint, Nature Aging 2024. Citation flow is accelerating: 54 citations in 2017–2018 concentrated on the UPR/immunosurveillance review, then a recent surge (51 in 2024, 22 in 2025), indicating rising visibility rather than plateau.

Publication Quality and Theme Coherence

The venue quality is genuinely strong: Trends in Cancer review on the unfolded protein response in tumor immunosurveillance (54 citations, her most-cited work, though she is a middle author) UPR in tumor immunosurveillance review, Trends in Cancer 2017; PNAS on MAVS deficiency and dysbiotic gut microbiota driving allergy MAVS deficiency, dysbiosis and allergy, PNAS 2018; Nature Communications on type III interferon priming pDCs against TGF-β/PGE2 suppression IFN-λ primes pDCs vs tumor suppression, Nat Commun 2025; and Journal for ImmunoTherapy of Cancer on MDR1⁺ Th1.17 CD4 T cells resisting neoadjuvant chemotherapy MDR1+ CD4 T cells and chemoresponse, JITC 2023. The thematic program is coherent and increasingly sophisticated: innate immunosurveillance of stressed/senescent/pre-neoplastic cells, spanning NK cells, pDCs, neutrophil–platelet aggregates, and inflammasome–circadian biology.

Authorship Position and What It Means

A critical caveat: across all indexed works, Moudombi appears exclusively in middle-author positions, with no first- or last-authorship visible. The most-cited works are led by others (Iltis, Vanacker, Sakref, Plantamura, Lecot). Her h-index of 6 therefore reflects productive participation in strong teams (Centre Léon Bérard / Lyon 1 / CNRS / INSERM network, including Christophe Caux and Marie-Cécile Michallet groups) rather than independent scientific leadership. Conversely, three bioRxiv preprints suggest active ongoing projects, including ST2⁺ IL-33-responsive NK cells potentiating immunotherapy responses IL-33-responsive ST2+ NK cell state preprint, bioRxiv 2023 and the senescence-associated ganglioside checkpoint (preprint-to-Nature Aging pipeline) Senescence ganglioside checkpoint preprint, bioRxiv 2021.

Blind Spots in This Assessment

• No ORCID or primary institution is indexed, and OpenAlex shows a second zero-citation profile — possible author-disambiguation fragmentation means metrics are approximate.
• No Cloris/Scopus overlap check was possible; per-year citation counts come from a single bibliographic source.
• Absence of first-author papers in the record may reflect indexing gaps rather than reality — independence cannot be judged without full CV-level data.
• Mouse models and human cohorts differ; the preclinical translational claims (e.g., NPA gene signatures in cancer prognosis) require validation cohorts.

Bottom line: evidence of high-quality collaborative science in respected labs with a rising citation curve (confidence: moderate — based on bibliographic indices alone, with authorship-position ambiguity as the main unknown). What would change this conclusion: documented first/last-author articles or independent grants would upgrade the independence assessment; conversely, failure of the Nature Aging ganglioside-checkpoint findings to replicate would deflate the strongest citation pillar.

 BGPT Author Review

Scientific Quality

h-index 6 with ~194 citations across 19 works is respectable for an early-career researcher, but every indexed paper places her as a middle author; scientific leadership and independent hypothesis-generation cannot be demonstrated from the record. Venue quality (Nature Aging, Nature Communications, PNAS, Trends in Cancer) is genuinely strong and indicates she operates within high-performing labs with rigorous experimental standards. Score reflects excellent collaborative science with unproven independence.

Communication Quality

Contributions to clear, well-cited reviews (Trends in Cancer) and open-access gold articles suggest competent science writing. However, no sole-authored or first-authored communication exists to evaluate her individual clarity; scoring is inferred from team output.

Author Novelty

The ganglioside-based senescence immune checkpoint in Nature Aging is a genuinely novel mechanism (senescent cells evading NK clearance during aging), and the circadian-CRY/NLRP3 inflammasome checkpoint concept is original. However, as a middle author, her personal conceptual contribution versus execution is indeterminate.

Scientific Rigor

Publication in PNAS, Nature Communications, and Nature Aging implies passing demanding peer review with mechanistic depth (microbiota causality, cytokine signaling, multi-omics). Rigor of her personal contributions cannot be isolated; several works remain preprints (ST2+ NK cell state) without peer review, and translational cohort studies carry sample-size and validation uncertainties.